Expert opinion on ulcerative colitis

Meet Dr Tim Raine

Chapter 1 – Meet Dr Tim Raine / Chapter 2 – Key challenges in UC management and their impact / Chapter 3 – Treatment goals and targets for UC management / Chapter 4 – Benefits and limitations of corticosteroids in UC / Chapter 5 – Current treatment options for UC / Chapter 6 – Targeted small molecules and biologics in UC / Chapter 7 – Clinical trials in UC: Design and key endpoints / Chapter 8 – Considerations for appropriate treatment selection

Gain insights into treatment options and challenges to achieving optimal care for people with ulcerative colitis (UC) with gastroenterologist Dr Tim Raine, from Cambridge University Hospitals in the UK. Review treatment goals that have the most impact on daily life for people with UC, explore the role of biologics and targeted small molecule treatments in UC management, and why it is important to understand each patient’s needs, priorities and preferences in treatment decision-making.

Meet Professor Stephen B. Hanauer

Chapter 1 – Meet Professor Stephen B. Hanauer / Chapter 2 – Key unmet needs in ulcerative colitis / Chapter 3 – Clinical trials for targeted small molecules in UC / Chapter 4 – Clinical trials for biologics in UC / Chapter 5 – Approvals for targeted small molecules in UC / Chapter 6 – Individualised treatment selection in UC / Chapter 7 – The importance of timely treatment progression

What is the impact of unmet needs on the management of moderate-to-severe UC, and why is timely treatment progression important? Join gastroenterologist Professor Stephen Hanauer, from Northwestern University’s Feinberg School of Medicine in the USA, as he explores the impacts of delayed access to biologics and targeted small molecules in the US context, as well as clinical trial evidence for UC treatments and individualised treatment selection in UC.

Learn more about unmet needs in UC management

Explore the role of biologics and targeted small molecules in UC

Learn more about Dr Raine and Professor Hanauer